January, 23 2015, 01:45pm EDT
For Immediate Release
Contact:
Tim Shenk,Press Officer,Direct: 212-763-5764,E-mail:,tim.shenk@newyork.msf.org
Ahead of Obama Visit, MSF Warns US Pressure on India Could Impact Access to Medicines for Millions
Ahead of US president Obama's visit to India, the international medical humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF) expressed deep concern over the US government's heightened efforts to undermine access to affordable medicines from India--often called the "pharmacy of the developing world." Millions of people across the globe rely on Indian low-cost generics, just as MSF relies on these to carry out its medical work.
NEW DELHI
Ahead of US president Obama's visit to India, the international medical humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF) expressed deep concern over the US government's heightened efforts to undermine access to affordable medicines from India--often called the "pharmacy of the developing world." Millions of people across the globe rely on Indian low-cost generics, just as MSF relies on these to carry out its medical work.
The US has been scaling up pressure on India and increasing visits to the country over the last several months in order to aggressively campaign against India's patent law. The country's law sets a high bar for what merits a patent in an effort to prevent abusive pharmaceutical patenting practices, such as "evergreening," which put profit over public health by blocking production of more affordable generics. The US is pushing for India to adopt intellectual property (IP) measures similar to those common in the US and EU, which would ultimately result in unaffordable medicine prices for both India and the countries that rely on affordable medicines made in India.
"The alarm bells should be going off for the new Indian government," said Dr. Manica Balasegaram, executive director of MSF's Access Campaign. "The US is pushing India to play by its rules on intellectual property, which we know will lead to medicines being priced out of reach for millions of people."
US pressure already appears to be having an impact: the new Indian government has been delaying a decision to allow generic production of an exorbitantly priced patented anti-cancer medicine that is unaffordable in the country--an action recommended by a Health Ministry expert committee to increase access to affordable versions. A "compulsory licence" issued by the Patent Controller in 2012 for an unaffordable cancer drug brought its price down by 97 percent almost instantly.
Click Here to Read the Briefing Document: PERSISTENT US ATTACKS ON INDIA'S PATENT LAW & GENERIC COMPETITION
Also in response to US pressure, the Indian Commerce Minister in November set up a high-level "think tank" to draft national IP policy. The first draft of the policy recently released is alarming. It emphasizes patent monopolies as the key driver of innovation, when such claims have been refuted by numerous studies and experts at the World Health Organization, which have found IP in fact to be a barrier to both access to affordable medicines and innovation for medicines desperately needed by developing countries for diseases such as tuberculosis.
"We need the Indian government to pay very careful attention to what the US is up to right now," said Rohit Malpani, director of policy and analysis for MSF's Access Campaign. "India has been a leader in promoting access to affordable medicines and new innovation models, but this could all unravel very fast if the Indian government caves in to US pressure. The think tank so far seems to be singing to Big Pharma's tune of undermining global efforts to finally overhaul today's system of how medicines are developed and priced."
At the same time, the Obama visit comes in the wake of a critical decision by India's Patent Controller to deny a patent to pharmaceutical company Gilead for the hepatitis C drug sofosbuvir--an example of how important India's law is to encouraging price-lowering generic competition. The drug is priced in the US at US$84,000 for a three-month treatment course ($1,000 per pill), though studies estimate its production for a three-month course could cost as little as $101 (about $1 per pill). The UK's National Health Service is delaying introduction of the drug because of its cost, and protests have erupted in Spain over the drug's rationing as a result of its price.
Unsurprisingly, discontent is already being expressed, and the patent rejection is likely to be brought up by US officials accompanying President Obama.
"India's decision to reject the patent for the hepatitis C drug sofosbuvir could unleash fierce competition among Indian companies to launch affordable versions of the life saving drug this year," said Leena Menghaney, South Asia Manager of MSF's Access Campaign. "Let the exorbitant prices being charged for this hepatitis C drug in many countries serve as a cautionary tale to India--this is what could happen here if the US succeeds and gets India to change its policies. India now faces a challenge: future access to essential medicines for millions of people will depend on the new Indian government's decisions and the kind of patent and innovation system it endorses."
Doctors Without Borders/Medecins Sans Frontieres (MSF) is an international medical humanitarian organization created by doctors and journalists in France in 1971. MSF's work is based on the humanitarian principles of medical ethics and impartiality. The organization is committed to bringing quality medical care to people caught in crisis regardless of race, religion, or political affiliation. MSF operates independently of any political, military, or religious agendas.
LATEST NEWS
‘Pretty Explicit White Nationalism’: Trump National Security Strategy Document Leaves Critics Aghast
One critic described the document as "a pretty explicit defense of using the state as a means of enforcing white supremacy."
Dec 05, 2025
The Trump administration on Thursday released its official National Security Strategy, and many critics noted that it was loaded with rhetoric frequently used by white nationalists.
Some of the most inflammatory rhetoric in the document is aimed at US-allied European countries that supposedly face "the real and more stark prospect of civilizational erasure" within the next 20 years.
In particular, the document accuses the European Union of enacting policies "that undermine political liberty and sovereignty, migration policies that are transforming the continent and creating strife, censorship of free speech and suppression of political opposition, cratering birthrates, and loss of national identities and self-confidence."
The document goes on to claim that "should present trends continue, the continent will be unrecognizable in 20 years or less," while emphasizing that US policy is to help "Europe to remain European, to regain its civilizational self-confidence, and to abandon its failed focus on regulatory suffocation."
Jon Henley, Europe correspondent for the Guardian, noted in a Friday report that the document "appears to espouse the racist 'great replacement' conspiracy theory, saying several countries risk becoming 'majority non-European.'" Henley added that the document "underscores the Trump administration's clear alignment with Europe’s far-right nationalist parties, whose policies centre on attacking supposed EU overreach and excessive non-EU migration."
Scott Horton, legal affairs and national security contributor to Harper's and an adjunct professor at Columbia Law School, wrote on Bluesky that the document "reads like something written by Vladimir Putin," given its depiction of Europe as being "degenerate and... racially adulterated through the in-migration of dark-skinned people."
Progressive activist Max Berger argued that the document "contains some pretty explicit white nationalism." He pointed to the document's support for dismantling diversity, equity, and inclusion (DEI) initiatives as a way to restore "a culture of competence."
Berger also flagged a section in the document that named "ending mass migration" as the top US national security priority, which he described as "a pretty explicit defense of using the state as a means of enforcing white supremacy."
Edmund Luce, a columnist for the Financial Times, also took note of the administration's emphasis on "competence and merit" in the document. This is ironic, Luce continued, because "this administration personifies the opposites" of those traits.
Journalist Michael Weiss argued in a post on X that the document shows that it is now official US policy to promote and assist far-right parties in Europe.
"[US Vice President] JD Vance's intervention in Germany's election, on behalf of [far-right party Alternative für Deutschland], was not a one-off," he wrote. "It is now ingrained in the U.S. National Security Strategy... Europe is be treated as enemy terrain to be destabilized by America's enabling of far-right parties."
Keep ReadingShow Less
Global System 'Rigged for the Wealthy' Delivers World With 'More Billionaires Than Ever'
New annual report on "ambitions" of billionaires by wealth management giant UBS shows just 2,919 individuals have a combined wealth of $15.8 trillion.
Dec 05, 2025
A new assessment by the international wealth management giant UBS this week shows that the number of billionaires in the world has reached new heights and that the acceleration of inherited wealth represents a new chapter for the ultra-rich in the 21st Century.
The latest UBS Billionaire Ambitions Report, unveiled Thursday, details how just 2,919 individual billionaires have a combined wealth of $15.8 trillion. The number of billionaires in the world is up nearly 9 percent from the previous year. In the United States—where nearly a third of those on the list reside—924 billionaires hold a collective $6.9 trillion in wealth.
The assessment by UBS—which surveyed its own billionaire clients as part of the survey, now its eleventh edition—emphasizes a surge of inherited wealth among the billionaire class. According to the report:
In 2025, 91 heirs (64 of them male and 27 female) inherited a record USD 297.8 billion. That’s 36% more than in 2024, despite fewer people inheriting overall. Globally, inheritance bolstered the number of multigenerational billionaires, with some 860 multi-generational billionaires now overseeing total assets of USD 4.7 trillion. That’s up from 805 with USD 4.2 trillion in 2024.
Across the world, multi-generational billionaires are slowly extending down the generations, with the number of second-generation billionaires growing by 4.6% in the 2025 report, the number of third generation
by 12.3%, and the number of fourth generation and beyond by 10%.
The growing number of billionaires, including a rapidly increasing share who inherited their wealth rather than generating it themselves, says UBS, "heralds a new era" for the ultra-rich as "the great wealth transfer is intensifying as heirs inherit more than ever before.
The coming decades, the report notes, "will see growing numbers of billionaires and centi-millionaires as the Great Wealth Transfer continues to accelerate. Billionaires are estimated to transfer approximately USD 6.9 trillion of wealth globally by 2040, with at least USD 5.9 trillion set to be passed to children—either directly or indirectly through spouses."
Of the $6.9 trillion currently held by US billionaires, the report estimates that $2.8 trillion of that wealth will be passed down to heirs over the next 15 years.
"The world has more billionaires than ever because of a system that’s broken for workers and rigged for the wealthy and CEOs who already make 285 times what workers do," said the AFL-CIO in response to the report.
The union federation says that organized workers winning better collective bargaining is the first step needed to "level the playing field" for working people, while others see the surging fortunes of the ultra-wealthy as just more evidence that taxing the rich must remain at the top of the economic and political agenda both at the national level and internationally.
With the UBS report showing that 91 of the new billionaires created this year arrived at their financial status through inheritance, Hal Singer, economics professor at the University of Utah, said, "That's 91 additional reasons for a wealth tax."
Keep ReadingShow Less
Outrage Grows as Trump Admin Quietly Weighs New 'Tax Windfall for the Biggest Corporations'
"Apparently the Trump administration thinks the trillions they spent on tax cuts for the wealthy wasn't enough."
Dec 05, 2025
The Trump administration's quiet effort to deliver billions more in tax breaks to some of the largest companies in the United States drew fresh scrutiny and outrage this week, with Democratic members of Congress warning that a series of obscure regulatory changes could further undermine efforts to rein in corporate tax dodging.
In a letter to the US Treasury Department unveiled Thursday, Sen. Elizabeth Warren (D-Mass.) and Rep. Don Beyer (D-Va.) led a group of lawmakers in denouncing the Trump administration's assault on the corporate alternative minimum tax (CAMT), a Biden-era measure that requires highly profitable US corporations to pay a tax of at least 15% on their book profits—the numbers reported to shareholders.
"The Trump administration has consistently chipped away at CAMT to further corporate interests," the lawmakers wrote, pointing to rules issued in recent months exempting many corporations from the tax.
"But these massive giveaways apparently aren’t enough for billionaire corporations and their lobbyists, which are trying to further undermine CAMT," the lawmakers continued.
The Democratic lawmakers, who were joined by Sen. Bernie Sanders (I-Vt.), specifically warned against an ongoing corporate push for a carveout to a research and experimentation (R&E) tax break included in the Trump-GOP budget law enacted over the summer.
Corporations supported the R&E tax break. But as the Wall Street Journal reported last month, the giveaway is driving some companies' "regular taxes down so far that they are pushed into CAMT."
"This is exactly what CAMT was designed to do, the tax’s defenders say," the Journal noted. "Companies are pressing the Treasury Department for relief, particularly on the way that CAMT limits the deduction for research expenses. The National Association of Manufacturers, the R&D Coalition, and the National Foreign Trade Council sent letters urging the administration to write rules that would be favorable to companies."
The Treasury Department and Internal Revenue Service are reportedly considering the corporate proposal.
Such a change, Democratic lawmakers warned in their new letter, "egregiously circumvents Congress' intent to set a floor on corporations’ tax liabilities regardless of deductions."
But the Trump administration's hostility to the CAMT, cozy relationship with powerful corporations, and willingness to trample existing law have fueled concerns that it will readily bow to industry demands.
"Apparently the Trump administration thinks the trillions they spent on tax cuts for the wealthy wasn't enough now they're planning another huge tax windfall for the biggest corporations in the country," Beyer said Thursday.
In a social media post, Warren wrote that "giant corporations are lobbying Donald Trump for yet another tax handout—this time for research they've ALREADY DONE."
"Give me a break," Warren added. "The last thing American families need is a tax code rigged even more for billionaires and billionaire corporations."
Keep ReadingShow Less
Most Popular